Cancer

Hormone Profiles in Hormone-dependent Cancers, Barnett Zumoff, MD, Cancer Research, 11/1975, Volume 35(11pt2), Pages 3365-73. *

Hormonal Profiles in Women with Breast Cancer, Barnett Zumoff, MD, Contemporary Management of Breast Cancer Disease: Breast Cancer, 12/1994, Volume 21(4), Pages 3365-73. *

The Role of Hormone Replacement Therapy in the Risk for Breast Cancer and Total Mortality in Women with a Family History of Breast Cancer, Thomas Sellers, PhD, Annals of Internal Medicine, 12/1997, Volume 127, Pages 973-980. *

Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk, Catherine Schairer, PhD., JAMA, 01/2000, Volume 283(4), Pages 485-491. *

Postmenopausal Estrogens - Opposed, Unopposed, or None of the Above, Walter Willer, MD, DrPH, JAMA, 01/2000, Volume 283(4), Pages 534-535. *

Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy, Raphael C. Guzman, PNAS - Proceedings of the National Academy of Sciences, 03/1999, Volume 96, Pages 2420-25. *

Breast Cancer Diagnosed During Hormone Replacement Therapy, Csaba Gajdos, MD, No reference available - The Mount Sinai Medical Center NYC, 04/2000, Volume 95(4), Pages 513-18. *

Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women, Carmen Rodriguez, MD, MPH, JAMA, 03/2001, Volume 285(11), Pages1460-65. *

A Case-Control Study of Combined Continuous Estrogen-Progestin Replacement Therapy among Women with a Personal History of Breast Cancer, John A. Eden, The Journal of the North American Menopause Society, 1995, Volume 2(2), Pages 67-72. *

Human Papillomavirus and Long-term Oral Contraceptive use Increase the Risk of Adenocarcinoma in Situ of the Cervix, Margaret M. Madeleine, Cancer Epidemiology, Biomarkers & Prevention, 03/2001, Volume 10, Pages 171-77. *

Endometrial Cancer: Hormonal Factors, the Perimenopausal "Window of Risk" and Isoflavones, G.E. Hale, The Journal of Clinical Endocrinology & Metabolism, 2002, Volume 87(1), Pages 3-15. *

Hormone Replacement Therapy in Relation to Breast Cancer, Chi-Ling Chen, PhD, JAMA, 02/2002, Volume Pages N/A. *

Independent US panel fans debate on mammography, Faith McLellan, The Lancet, 02/2002, Volume 359, Pages 409. *

X-Ray Vision in Hindsight: Science, Politics, and the Mammogram, Gina Kolata, The New York Times, 02/11/2002, Volume Date N/A. *

More Debate over Mammograms, The Associated Press, The New York Times, 02/22/2002, Volume Pages N/A. *

Christine Gorman, Rethinking Breast Cancer, Time, 02/18/2002. *

Study Shows Greater Risk of Breast Cancer with Estrogen-Progestin Therapy Compared to Estrogen Alone, National Cancer Institute - Press Release, 01/28/2000, Volume Pages N/A. *

Estrogen Replacement Therapy in Women with Previous Breast Cancer, PK Natrajan, American Journal of Obstetrics & Gynecology, 08/1999, Volume 181(2), Pages 288-95. *

Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy, MJ Nachtigall, Obstetrics & Gynecology, 11/1992, Volume 81(3), Pages 827-30. *

Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users, RD Gambrell, Obstetrics & Gynecology, 10/1983, Volume 62(4), Pages 435-43. *

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin, RK Ross, Journal of National Cancer Research, 02/2000, Volume 92(4), Pages 328-332. *

Hormone Replacement Therapy and Breast Cancer, RD Gambrell, Maturitas, 08/1987, Volume 9(2), Pages 123-33. *

Breast carcinoma developing in patients on hormone replacement therapy; a histological and immunohistological study, IF O'Connor, Journal of Clinical Pathology, 12/1998, Volume 51(12), Pages 935-38. *

Low biologic aggressiveness in breast cancer in women using hormone replacement therapy, K Holli, Journal of Clinical Oncology, 09/1998, Volume 16(9), Pages 3115-20. *

Sex hormone-binding globulin: not only a transport protein. What news is around the corner?, N. Fortunati, Journal of Endocrinological Investigation, 03/1999, Volume 22(3), Pages 223-34. *

A prospective study of estradiol and breast cancer in Japanese Women, P Mauvais-Jarvis, Annals of New York Academy of Sciences, 1986, Volume 464, Pages 152-167. *

Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications, JR Pasqualini, Journal of Steroid Biochem Mol Biol, 04/1999, Volume 69(1-6), Pages 287-92. *

Steroid hormone receptors in breast cancer management, CK Osborne, Breast Cancer Research and Treatment, 1998, Volume 51(3), Pages 227-238. *

Steroid hormone receptor status and other immunohistochemical prognostic markers in benigh and malignant diseases of the breast, H. Nizze, Zentralblatt fue Chirurgie, 06/2005, Volume 123(suppl. 5), pages 14-8. *

Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium, Helene B. Leonsetti, MD, Fertility and Sterility, 01/2003, Volume 79(1), Pages 221-222. *

Influences of Percutaneous Administration of Estradiol and Progesterone on Human Breast Epithelial Cell Cycle in Vivo, King-Jen Chang, Fertility and Sterility, 04/1995, Volume 63(4), Pages 785-791. *

Breast Cancer Incidence in Women with a History of Progesterone Deficiency, Linda D. Cowan, American Journal of Epidemiology, 1981, Volume 114(2), Pages 209-19. *

Serum Progesterone and Prognosis in Operable Breast Cancer, PE Mohr, British Journal of Cancer, 1996, Volume 73, 1552-55. *

The Influence of Progesterone and Androgens on the Growth of Endometrial Carcinoma, K. Boman MD, Cancer, 06/1993, Volume 71(11), Pages 3565-69. *

Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women, RL Balleine, British Journal of Cancer, 03/1999, Volume 79(9-10), Pages 1564-71. *

Estradiol and progesterone regulate the proliferation of human breast epithelial cells, JM Foidart, Fertility and Sterility, 05/1998, Volume 69(5), Pages 963-69. *

Oestriol and Prevention of Breast Cancer, Henry Lemon, The Lancet, 03/1973. *

Reduced Estriol Excretion in Patients with Breast Cancer prior to Endocrine Therapy, Henry Lemon, JAMA, 06/27/1966, Volume 196(12), Pages 112-120. *

Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma, Acta Endocrinologica, 1980, Volume 233, Pages 17-27. *

Molecular and Kinetic Basis for the Mixed Agonist/Antagonist Activity of Estriol, Michal Melamed, Molecular Endocrinology, 1997, Volume 11(12), Pages 1868-78. *

Antimammary Carcinogenic Activity of 17-Alpha-Ethinyl Estriol, Henry Lemon, Cancer, 1987, Volume 60, Pages 2873-81. *

Estrogen Profiles of Oriental and Caucasian Women in Hawaii, Louis F. dickinson, MD, The New England Journal of Medicine, 12/1974, Volume 291(23), Pages 1211-14. *

Clinical and experimental aspects of the anti-mammary carinogenic activity of estriol, Henry Lemon, Fron Rhorm Res., 1977, Volume 5(9), 155-73. *

Molecular Mechanisms of Estrogen Carcinogenesis, JD Yager, Ann Rev. Pharmaceut. Taxicol, 1996, 36, Pages 203-32. *

Molecular Mechanisms of Estrogen Carcinogenesis, J.D. Yager, Ann Rev. Pharmaceut. Taxicol, 1996, Volume 36, Pages 203-32. *

16x-Hydroxylation of Estradiol: A Possible Risk Marker for Breast Cancer, H.L. Bradlow, Annals of New York Academy of Sciences, Date Volume N/A, Pages 138-51. *

Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breast cancer risk, H.L. Bradlow, Environmental Health Perspectives, 10/1995, Volume 103(Suppl 7), Pages 147-50. *

Estrogenic and antiestrogenic activities of 16 alpha and 2-hydroxy metaboloites of 17 beta-estradiol in MCF-7 and T47D human breast cancer cells, M. Gupta, Journal of Steroid Biochemistry and Molecular Biology, 12/1998, Volume 67(5-6), Pages 413-419. *

The Effect of a Low Fat Diet on Estrogen Metabolism, C. Longcope, The Journal of Clinical Endocrinology & Metabolism, 06/1987, Volume 64(6), Pages 1246-50. *

Molecular origin of cancer: Catechol estrogen -3-4-quinones as endogenous tumor initiators, E.L. Cavalieri, PNAS - Proceedings of the National Academy of Sciences, 09/1997, Volume 94, Pages 10937-42. *

2-Hydroxyestrone: the "good" estrogen, H.L. Bradlow, Journal of Endocrinology, 1996, Volume 150, Pages S259-264. *

Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women, P. Muti, Epidemiology, 11/2000, Volume 11(6), Pages 635-40. *

2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression, T.L. Yue, Molecular Pharmacology, 06/1997, Volume 51(6), Pages 951-62. *

Alkylation of 2'-Deoxynucleosides and DNA by the Premarin Metabolite 4-Hydroxyequilenin Semiquinone Radical, Li Shen, Chemical Research in Toxicology, 1998, Volume 11, Pages 94-101. *

The equine estrogen metabolite 4-hydroxyequilenin causes DNA single-strand breaks and oxidation of DNA bases in vitro, Y. Chen, Chemical Research in Toxicology, 09/1998, Volume 11(9), Pages 1105-11. *

The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone, F. Zhang, Chemical Research in Toxicology, 02/1999, Volume 12(2), Pages 204-13. *

Synthesis of the equine estrogen metabolites 2-hydroxyequilin and 2-hydroxyequilenin, E. Pisha, Chemical Research in Toxicology, 02/1999, Volume 12(2), Pages 200-203. *

A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines, Y. Chen, Chemical Research in Toxicology, 05/2000, Volume 13(5), Pages 342-50. *

Evidence that a metabolite of equine estrogens, 4-hydroxyequilenin, induces cellular transformation in vitro, E. Pisha, Chemical Research in Toxicology, 01/2001, Volume 14(1), Pages 82-90. *

Bioreductive activation of catechol estrogen-ortho-quinones: aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity, L. Shen, Carcinogenesis, 05/1997, Volume 18(5), 1093-101. *

Inhibition of glutathione S-transferase activity by the quinoid metabolites of equine estrogens, M. Chang, Chemical Research in Toxicology, 06/1998, Volume 11(7), Pages 758-65. *

The Carcinogenic Activity of Ethinyl Estrogens Is Determined by Both Their Hormonal Characteristics and Their Conversion to Catechol Metabolites, Tao Ting Zhu, No reference info available, Date Volume N/A, Pages 577-83. *

5x-Reductases in Human Breast Carcinoma: Possible Modulator of in Situ Androgenic Actions, Takashi Suzuki, The Journal of Clinical Endocrinology & Metabolism, 2001, Volume 86(5), 768, Pages 180-200. *

Cabbages, Broccoli, et al., Versus Sex Hormone Related Cancers, Jonathan V. Wright, MD, Nutrition and Healing, 02/2000, Volume 7(2), Pages 8-Jan. *

Indole-3-carbinol. A novel approach to breast cancer prevention, H.L. Bradlow, Annals of New York Academy of Sciences, 09/1995, Volume 768, Pages 180-200.

Inhibition of Proliferation and Modulation of Estradiol Metabolism: Novel Mechanisms for Breast Cancer Prevention by the Phytochemical Indole-3-Carbinol, Nitin T. Telang, No reference info available, Date Volume N/A, 246-52. *

Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane, Ichen Chen, Carcinogenesis, 1998, Volume 19(9), Pages 1631-39. *

Nutritional Influences on Estrogen Metabolism, Couglas C. Hall, Applied Nutritional Science Reports, 2001, Volume N/A, Pages 1-8. *

Phytoestrogens: Epidemiology and a Possible Role in Cancer Protection, Herman Aldercreutz, Environmental Health Perspectives, 1995, Volume 103(suppl 7). *

Decreased Ovarian Hormones during a Soya Diet: Implications for Breast Cancer Prevention, Lee-Jane W. Lu, Cancer Research, 2000, Volume 60, 4112-21. *

Traditional and Alternative Therapies for Breast Cancer, Tieraona Low Dog, MD, Alternative Therapies, 05/2001, Volume 7(3), Pages 36-47. *

Breast Cancer Hypothesis: A single cause for the Majority of cases, Richard A. Wiseman, Journal of Epidemiology and Community Health, 2000, Volume 54, Pages 851-58. *

Indole-3-carbinol as a chemopreventive agent in 2-amino-1-methyl-6-phenylimidaxo [4,5-b] pyridine (PhIP) carcinogenesis: inhibition of PhIP-DNA adduct formation, acceleration of PhI metabolism, and induction of cytochrome P450 in female F344 rats, Y.H. He, Food and Chemical Toxicology, 01/2000, Volume 38(1), Pages 15-23. *

Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation, P.H. Jellininck, Biochemical Pharmacology, 04/1996, Volume 51(8), Pages 1069-76. *

Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice, L. Jin, Cancer Research, 08/1999, Volume 59(16), Pages 3991-7. *

3,3'-Diindolylmethane induces apoptosis in human cancer cells, X. Ge, 11/1996, Volume 228(1), 153-58. *

Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism, MA Kall, Carcinogenesis, 04/1996, Volume 17(4), Pages 793-99.

Epidemiology of soy and cancer: perspectives and directions, V. Persky, Journal of Nutrition, 03/1995, Volume 125(3 Suppl), pages 709S-712S. *

Environmental and Heritable Factors in the Causation of Cancer, Paul Lichtenstein, The New England Journal of Medicine, 07/2000, Volume 343(2), Pages 78-85. *

Cancer Chemoprevention with the Adrenocortical Steroid Dehydroepiandrosterone and Structural Analogs, Arthur G. Schwartz, Journal of Cellular Biology, 1993, Pages 709S-712S. *

Breast Cancer and the Role of Cytokines in Regulating Estrogen Synthesis: An Emerging Hypothesis, MJ Reed, Endocrine Reviews, 1997, Volume 18(5), Pages 701-15. *